Amphastar Pharmaceuticals... (AMPH)
Bid | 28.81 |
Market Cap | 1.36B |
Revenue (ttm) | 720.28M |
Net Income (ttm) | 134.71M |
EPS (ttm) | 2.67 |
PE Ratio (ttm) | 10.93 |
Forward PE | 8.13 |
Analyst | Hold |
Ask | 30.45 |
Volume | 541,299 |
Avg. Volume (20D) | 532,509 |
Open | 29.39 |
Previous Close | 29.39 |
Day's Range | 28.88 - 29.59 |
52-Week Range | 20.39 - 53.96 |
Beta | 0.76 |
About AMPH
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for AMPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

1 week ago · accessnewswire.com
Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be par...

3 weeks ago · accessnewswire.com
Amphastar Announces FDA Approval for Iron Sucrose Injection, USPAccording to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer ® for the treatment of iron deficiency anemia in patients with chr...

3 weeks ago · seekingalpha.com
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call TranscriptAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Commu...

4 weeks ago · accessnewswire.com
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025- Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025 - GAAP net income of $31.0 million, or $0.64 per share, for the second quarter - Adjusted non-GAAP net income of $40.9...